Assessing the risk of cancer transformation in chronic atrophic gastritis
Risk Assessment and Syndrome Evolution Models Combining Traditional Chinese Medicine and Modern Medicine Indicators for Chronic Atrophic Gastritis Malignant Transformation: a Registry Study
This study is trying to see if combining Traditional Chinese Medicine with modern medical practices can help predict the risk of cancer in people with chronic atrophic gastritis over ten years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Beijing University of Chinese Medicine Academic / other |
| Locations | 2 sites (Beijing, Beijing Municipality and 1 other locations) |
| Trial ID | NCT03261934 on ClinicalTrials.gov |
What this trial studies
This study aims to develop models for assessing the risk and syndrome evolution of malignant transformation in chronic atrophic gastritis (CAG) by integrating indicators from Traditional Chinese Medicine (TCM) and modern medical practices. It will involve a registry-based participant survey across four hospitals in Beijing, China, recruiting 2000 patients diagnosed with CAG. Participants will be followed for 10 years to monitor any malignant transformation events, with data collected through on-site visits and telephone follow-ups. The study will utilize various statistical analyses to explore the relationship between TCM and modern medicine indicators and the risk of malignant transformation.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 18-75 who have been diagnosed with chronic atrophic gastritis.
Not a fit: Patients with a history of stomach surgery or those unable to participate in data collection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the risk factors for gastric cancer in patients with chronic atrophic gastritis, potentially leading to improved prevention strategies.
How similar studies have performed: While the integration of TCM and modern medicine in assessing cancer risk is innovative, similar studies have not been widely conducted, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: (1) 18-75 years of age; (2) Meeting diagnostic criteria of CAG after upper gastrointestinal endoscopy; (3) Willing to cooperate with data, tissue sample, and blood sample collection during recruitment; (4) Willing to respond truthfully and timely to researcher queries after recruitment, able to cooperate with data, tissue sample and blood sample collection during follow-ups; (5) Willing to sign informed consent. Exclusion Criteria: (1) Meeting past history of previous stomach surgery; (2) Unable to participate in data, tissue sample or blood sample collection for any reason.
Where this trial is running
Beijing, Beijing Municipality and 1 other locations
- Dongzhimen Hospital — Beijing, Beijing Municipality, China (Recruiting)
- Wangjing Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Yin Zhang, MD
- Email: coolzhangyin@sina.com
- Phone: 86-17710830835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.